Indications for: DIPENTUM
Maintenance of remission in ulcerative colitis in patients intolerant of sulfasalazine.
500mg twice a day with meals.
Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly: monitor CBCs, platelets. Pregnancy. Nursing mothers: not recommended.
Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity; monitor CBCs, platelets if concomitant use is unavoidable. May cause elevated test results when measuring urinary normetanephrine; consider alternative assay. Increased risk of bleeding (eg, hematomas) following neuraxial anesthesia with low molecular weight heparins or heparinoids. Increased prothrombin time with warfarin; monitor and adjust dose. Increased risk of Reye’s syndrome with varicella vaccine; avoid for 6 weeks after varicella vaccine.
Diarrhea, abdominal pain, rash, pruritus; acute intolerance syndrome (cramping, bloody diarrhea, fever, headache, rash), renal impairment, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).
Generic Drug Availability: